12 May 2026 : Original article
A Retrospective Study of 518 Kidney Transplant Recipients to Evaluate the Association of Antiplatelet Therapy With Long-Term Cardiovascular Events and All-Cause Mortality
Gavin Christy BCEF 1, Andres Mata ABE 2, Zalan Shah B 1, Ananta M.H. Sriram B 1, Diana Pfeiffer B 1, Taylor R. Coffman
B 1, Madeline K. Johnson E 1, Sahita Gandra E 1, Krista L. Lentine ADEG 3, Mina M. Benjamin ADE 4*
DOI: 10.12659/AOT.951325
Ann Transplant 2026; 31:e951325
Table 3 Clinical outcomes at 60 months of follow-up among 518 kidney transplant recipients, stratified by exposure to antiplatelet therapy after transplantation. Primary prevention subgroups include patients without known cardiovascular disease.
| Outcomes (%) | No AP (n=343) | AP (n=175) | P value | No AP primary prevention (n=276) | AP primary prevention (n=92) | P value |
|---|---|---|---|---|---|---|
| Nonfatal myocardial infarction | 9 (3) | 6 (4) | 0.61 | 5 (1.8) | 2 (2.2) | 0.82 |
| Ischemic stroke | 7 (2) | 5 (3) | 0.23 | 4 (1.4) | 1 (1.1) | 0.51 |
| Unstable angina | 1 (0.3) | 4 (2) | 2 (0.7) | 2 (2.2) | 0.07 | |
| Coronary revascularization | 9 (2.6) | 6 (3.4) | 0.73 | 4 (1.4) | 1 (1.1) | 0.80 |
| Heart failure hospitalization | 18 (6) | 10 (6) | 0.96 | 14 (5.1) | 3 (3.3) | 0.93 |
| Sustained ventricular arrhythmia | 2 (0.6) | 3 (1.5) | 0.93 | 1 (0.4) | 1 (1.1) | 0.25 |
| Cardiovascular death | 9 (3) | 5 (3) | 0.69 | 6 (2.2) | 1 (1.1) | 0.84 |
| Total MACE | 40 (13) | 27 (17) | 0.62 | 28 (10.1) | 21 (22.8) | 0.77 |
| All-cause mortality | 31 (10) | 20 (10) | 0.59 | 25 (9.1) | 6 (6.5) | 0.30 |
| MACE+all-cause mortality | 76 (22) | 41 (24) | 0.88 | 53 (19.2) | 27 (29.3) | 0.80 |
| Major bleeding | 25 (8) | 12 (7) | 0.54 | 11 (4.0) | 6 (6.5) | 0.83 |
| Event rates are reported as number (percentage). AP – antiplatelet; MACE – major adverse cardiovascular events. | ||||||